Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Histamine
Drug ID BADD_D01071
Description A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Indications and Usage Histamine phosphate is indicated as a diagnostic aid for the evaluation of gastric acid secretory function.
Marketing Status approved; investigational
ATC Code L03AX14
DrugBank ID DB05381
KEGG ID D08040
MeSH ID D006632
PubChem ID 774
TTD Drug ID D04USC
NDC Product Code 65044-9998; 63083-1522; 81701-111
UNII 820484N8I3
Synonyms Histamine | Peremin | Histamine Dihydrochloride | Histamine Hydrochloride | Ceplene
Chemical Information
Molecular Formula C5H9N3
CAS Registry Number 51-45-6
SMILES C1=C(NC=N1)CCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Menopausal symptoms21.02.02.002---
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001---
Nervous system disorder17.02.10.001---
Neutropenia01.02.03.004---
Night sweats08.01.03.031; 23.02.03.006---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Pneumonia11.01.09.003; 22.07.01.003---
Pruritus23.03.12.001--
Rash23.03.13.0010.000637%-
Shock24.06.02.002---
Skin disorder23.03.03.007---
Stomatitis07.05.06.005--
Tachycardia02.03.02.007---
Thrombocytopenia01.08.01.002---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Lymphatic disorder01.09.01.003---
Musculoskeletal discomfort15.03.04.001---
Injection site swelling08.02.03.017; 12.07.03.018---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages